Loading...

New Site Coming Soon!

OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.

Our recent breakthroughs in applying native mass spectrometry to membrane proteins enable new applications of this technique to high-value receptors and drug targets. The technique provides unique insights regarding interactions which are challenging to obtain with other biophysical techniques

Technology

OMass uses the latest mass spectrometry instruments that have been modified to capture, transmit and detect intact proteins. These platforms have been developed cumulatively over 30 years of academic research. Non-covalent interactions between protein subunits and small molecules are preserved and observed directly, which provides an exciting opportunity to visualise complex, multicomponent binding networks within macromolecular assemblies.

OMass background

OMass Technologies was formed in 2016 as a spin-out from Oxford University with funding from OSI. It capitalized on the native mass spectrometry technology developed in the laboratory of Prof. Dame Carol Robinson used to investigate protein structures and their interactions. It was initially developed as a service company providing collaborative style consultancy to the pharmaceutical industry. OMass has worked with some of the major pharmaceutical companies in addition to helping smaller biotech companies with their drug discovery programmes.

Vacancies

COMPUTATIONAL CHEMIST
PROTEIN BIOCHEMIST
MASS SPECTROMETRY SCIENTIST
OFFICE MANAGER AND PA TO THE CEO
PROJECT MANAGER